Comparative long-term adverse effects elicited by invasive group B and C meningococcal infections.
about
Vaccinating Italian infants with a new multicomponent vaccine (Bexsero®) against meningococcal B disease: A cost-effectiveness analysisHealth and economic outcomes of introducing the new MenB vaccine (Bexsero) into the Italian routine infant immunisation programmeMonoclonal antibodies to meningococcal factor H binding protein with overlapping epitopes and discordant functional activityPrimary meningococcal polyarthritis in an adult woman.Capsular polysaccharide vaccine for Group B Neisseria meningitidis, Escherichia coli K1, and Pasteurella haemolytica A2.Meningococcal disease serogroup C.Unveiling New Aspects of Meningococcal Carriage and Disease PreventionCost-effectiveness of vaccination against meningococcal B among Dutch infants: Crucial impact of changes in incidence.Acute polyarthritis in a young patient caused by meningococcal and parvovirus B19 infections: a case report and review of the literature.Controlling serogroup B invasive meningococcal disease: the Canadian perspective.Bacterial meningitis in children in Iceland, 1975-2010: a nationwide epidemiological study.The Long Road to an Effective Vaccine for Meningococcus Group B (MenB).The Health Burden of Invasive Meningococcal Disease: A Systematic Review.Background Paper for the update of meningococcal vaccination recommendations in Germany: use of the serogroup B vaccine in persons at increased risk for meningococcal disease.Outcomes of invasive meningococcal disease in adults and children in Canada between 2002 and 2011: a prospective cohort study.Aktualisierung der Meningokokken-Impfempfehlung gemäß der STIKO
P2860
Q26779489-2B52011D-791F-4FA7-9909-E72CB4C79930Q28391723-E7001934-4DCB-401F-BD46-6AFFD24453E8Q28730934-42043166-C2BC-4F8D-97B0-65E0525B9F14Q35206878-C409CB51-BDAB-4A4B-BB86-72E1AFA456BFQ35518459-46AE21D1-04FF-47C7-BD71-467DFBB73394Q35832179-3D32C1F9-74C0-450B-89C5-CD793DAFA997Q36434449-92FC5B37-BB75-4E54-B541-36AC76549406Q37505414-C8E24BD2-6AA6-4171-9781-4A15E194AF04Q37522882-387F6FA8-6394-4DC7-BA8A-E060CD312271Q38105338-FE645049-6EFB-4439-B734-90C9C0CD1F09Q38130726-84F8A1ED-3B75-4A3A-8DA2-39270FCAC929Q38335257-0156FD58-2FDE-4765-948E-A45CE0350AA3Q38616399-F9926D2D-603E-4990-AAF2-0ADE769B34D4Q40408137-61C2AFE1-99AA-4C7B-8B5F-7D554996CB16Q41531696-F4D956F9-F85A-4DF2-BF6B-533E06301A1DQ55109692-8E31A308-5F8C-4D26-83A0-03F8CBD1F19F
P2860
Comparative long-term adverse effects elicited by invasive group B and C meningococcal infections.
description
2011 nî lūn-bûn
@nan
2011 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Comparative long-term adverse ...... nd C meningococcal infections.
@ast
Comparative long-term adverse ...... nd C meningococcal infections.
@en
type
label
Comparative long-term adverse ...... nd C meningococcal infections.
@ast
Comparative long-term adverse ...... nd C meningococcal infections.
@en
prefLabel
Comparative long-term adverse ...... nd C meningococcal infections.
@ast
Comparative long-term adverse ...... nd C meningococcal infections.
@en
P2093
P2860
P356
P1476
Comparative long-term adverse ...... nd C meningococcal infections.
@en
P2093
Hafrun Kristjansdottir
Ingi K Reynisson
John B Robbins
Jon F Sigurdsson
Mark A Miller
Martina V Nardini
Ragnar F Ingvarsson
P2860
P304
P356
10.1093/CID/CIR500
P407
P577
2011-09-26T00:00:00Z